医脉通编译，转载请务必注明出处。
2015年第75届美国糖尿病协会（ADA）科学年会在美国波士顿召开。北京大学人民医院内分泌代谢科纪立农教授团队的的一项荟萃分析结果在ADA2015年会普通壁报专场（General Poster Session）上发布。该研究通过对248项研究的荟萃分析，评估2型糖尿病降糖治疗中的安慰剂效应。以下是研究摘要译文。
目的：安慰剂是指对于疾病没有确切的药物治疗作用、但可能产生非特异性心理或生理积极作用的治疗手段。本研究旨在评估2型糖尿病降糖治疗中安慰剂的影响。
方法：入选MEDLINE、EMBASE及CENTRAL数据库2013年12月之前的研究。所有研究都是双盲、有安慰对照、在2型糖尿病患者中开展的研究，研究持续时间≥12周、且采用与基线相比HbA1c的变化来评估降糖疗效。最终有248项研究入选。
结果：在对比磺脲类药物与安慰剂的研究中，安慰剂治疗使HbA1c降低0.03%（95% CI, −0.37% to 0.44%, p>0.05）；在对比
结论：该荟萃分析为2型糖尿病降糖治疗中的安慰剂效应提供了全面临床证据。安慰剂治疗可使HbA1c降低0.03%，但无显著统计学意义。
【研究摘要】
| Abstract Number: | 1137-P |
| Title: | Placebo Effect of Hypoglycemic Drugs in Type 2 Diabetes—A Meta-analysis |
| Authors: | XIAOLING CAI, WENJIA YANG, LINGLI ZHOU, XUEYAO HAN, LINONG JI, Beijing, China |
| Abstract: | Placebo has been defined as any therapy that is used for its nonspecific psychological and physiologic effect but has no specific pharmacologic impact on the condition being treated. The aim of this study is to evaluate placebo effect of hypoglycemic treatment in type 2 diabetes. The MEDLINE®, EMBASE®, CENTRAL were searched until Dec 2013 and qualified studies were included. All the studies were double blind, placebo-controlled randomized trials in type 2 diabetes patients; study length of ≥12 weeks with the efficacy evaluated by changes in HbA1c from baseline in groups. 248 studies were included. In studies compared SU with placebo, treatment with placebo led to a HbA1c change of 0.03% (95% CI, −0.37% to 0.44%, p>0.05); in studies compared MET with placebo, treatment with placebo led to a HbA1c change of 0.19% (95% CI, −0.18% to 0.57%, p>0.05); in studies compared AGI with placebo, treatment with placebo led to a HbA1c change of 0.06% (95% CI, −0.12% to 0.23%, p>0.05); in studies compared TZD with placebo, treatment with placebo led to a HbA1c change of 0.09% (95% CI, -0.06% to 0.23%, p>0.05); in studies compared DPP-IV inhibitors with placebo, treatment with placebo led to a HbA1c change of -0.09% (95% CI, -0.20% to 0.03%, p>0.05); in studies compared SGLT2 with placebo, treatment with placebo led to a HbA1c change of -0.26% (95% CI, -0.54% to 0.02%, p>0.05); in studies compared GLP-1 analogue with placebo, treatment with placebo led to a HbA1c change of -0.11% (95% CI, -0.30% to 0.08%, p>0.05). Totally, in all studies, treatments with placebo led an HbA1c change from baseline of -0.03% without significance (95% CI, -0.17% to 0.11%, p>0.05). Meta-regression analyses revealed that the age of patients and percentage of female were negatively associated with HbA1c changes from baseline in placebo group. This meta-analysis provided comprehensive clinical evidence on placebo effect of hypoglycemic treatment in type 2 diabetes. Treatment with placebo led an HbA1c change from baseline of -0.03% without significance. |
会议专题>>>2015年美国糖尿病协会（ADA）年会
(本网站所有内容，凡注明来源为“医脉通”，版权均归医脉通所有，未经授权，任何媒体、网站或个人不得转载，否则将追究法律责任，授权转载时须注明“来源：医脉通”。本网注明来源为其他媒体的内容为转载，转载仅作观点分享，版权归原作者所有，如有侵犯版权，请及时联系我们。)
